CD79A and cancer: However, in the present study IgA positivity did not correlate with increased mortality, likely due to patient‐specific therapeutic approaches, including treatments for pre‐existing conditions (e.g., cancer, autoimmune therapies) and bleeding‐related interventions (e.g., porcine or human FVIII concentrates, emicizumab).